Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hojas, Sabine"" wg kryterium: Autor


Wyświetlanie 1-6 z 6
Tytuł :
Monitoring of minimal residual disease in patients with MLL–AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction.
Autorzy :
Mitterbauer, Gerlinde
Zimmer, Christine
Pirc-Danoewinata, Hendrati
Haas, Oskar A.
Hojas, Sabine
Schwarzinger, Ilse
Greinix, Hildegard
Jäger, Ulrich
Lechner, Klaus
Mannhalter, Christine
Pokaż więcej
Temat :
LEUKEMIA
POLYMERASE chain reaction
FLUORESCENCE in situ hybridization
BONE marrow transplantation
Źródło :
British Journal of Haematology. Jun2000, Vol. 109 Issue 3, p622-628. 7p. 2 Diagrams, 1 Graph.
Czasopismo naukowe
Tytuł :
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.
Autorzy :
Perakis SO; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Weber S; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Zhou Q; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Graf R; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Hojas S; Department of Internal Medicine, LKH Fuerstenfeld, Fuerstenfeld, Austria.
Riedl JM; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Gerger A; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Dandachi N; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Balic M; Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
Hoefler G; Institute of Pathology, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Schuuring E; Department of Pathology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
Groen HJM; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
Geigl JB; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Heitzer E; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria; Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Graz, Austria; BioTechMed-Graz, Graz, Austria. Electronic address: .
Speicher MR; Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria. Electronic address: .
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2020 Sep; Vol. 5 (5), pp. e000872.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
Autorzy :
Pleyer L; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. .; Cancer Cluster, Salzburg 5020, Austria. .
Döhner H; Department of Medicine and Internal Medicine III, Universitätsklinikum Ulm, Ulm D-89081, Germany. .
Dombret H; Institut Universitaire d'Hématologie, Hôpital Saint Louis, University Paris Diderot, Paris 75010, France. .
Seymour JF; Peter MacCallum Cancer Centre, East Melbourne, Australia, and University of Melbourne, Parkville 3000, Australia. .
Schuh AC; Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. .
Beach CL; Celgene Corporation, Summit, NJ 07901, USA. .
Swern AS; Celgene Corporation, Summit, NJ 07901, USA. .
Burgstaller S; Department of Internal Medicine IV, Klinikum WelsGrieskirchen, Wels 4600, Austria. .
Stauder R; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck 6020, Austria. .
Girschikofsky M; Department of Hematology and Oncology, Elisabethinen Hospital, Linz 4020, Austria. .
Sill H; Department of Hematology, Medical University of Graz, Graz 8036, Austria. .
Schlick K; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. .
Thaler J; Department of Internal Medicine IV, Klinikum WelsGrieskirchen, Wels 4600, Austria. .
Halter B; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck 6020, Austria. .
Machherndl Spandl S; Department of Hematology and Oncology, Elisabethinen Hospital, Linz 4020, Austria. .
Zebisch A; Department of Hematology, Medical University of Graz, Graz 8036, Austria. .
Pichler A; Department for Hematology and Oncology, LKH Leoben, Leoben 8700, Austria. .
Pfeilstöcker M; 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna 1140, Austria. .
Autzinger EM; First Medical Department, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna 1160, Austria. .
Lang A; Department of Internal Medicine, Landeskrankenhaus Feldkirch (LKH) Feldkirch, Feldkirch 6800, Austria. .
Geissler K; 5th Medical Department, Hospital Hietzing, Vienna 1130, Austria. .
Voskova D; Department of Internal Medicine III, General Hospital, Linz 4020, Austria. .
Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna 1090, Austria. .
Hojas S; Department of Internal Medicine, LKH Fürstenfeld, Fürstenfeld 8280, Austria. sabineelisabeth.hojas@kages.at.
Rogulj IM; Department of Hematology, Clinical Hospital Merkur, Zagreb 10000, Croatia. .
Andel J; Department of Internal Medicine II, LKH Steyr, Steyr 4400, Austria. .
Greil R; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University, Salzburg 5020, Austria. .; Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg 5020, Austria. .; Cancer Cluster, Salzburg 5020, Austria. .
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2017 Feb 15; Vol. 18 (2). Date of Electronic Publication: 2017 Feb 15.
Typ publikacji :
Journal Article
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Austria ; Azacitidine/administration & dosage ; Bone Marrow/pathology ; Clinical Trials, Phase III as Topic ; Female ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Proportional Hazards Models ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Autorzy :
Pleyer L; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria. .; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria. .; Cancer Cluster Salzburg, Salzburg, Austria. .
Burgstaller S; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Stauder R; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
Girschikofsky M; Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria.
Sill H; Department of Hematology, Medical University of Graz, Graz, Austria.
Schlick K; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
Thaler J; Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria.
Halter B; Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria.
Machherndl-Spandl S; Department of Hematology and Oncology, Elisabethinen Hospital, Linz, Austria.
Zebisch A; Department of Hematology, Medical University of Graz, Graz, Austria.
Pichler A; Department for Hematology and Oncology, LKH Leoben, Leoben, Austria.
Pfeilstöcker M; 3rd Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.
Autzinger EM; First Medical Department, Center for Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria.
Lang A; Department of Internal Medicine, LKH Feldkirch, Feldkirch, Austria.
Geissler K; 5th Medical Department, Hospital Hietzing, Vienna, Austria.
Voskova D; Department of Internal Medicine III, General Hospital, Linz, Austria.
Geissler D; 1st Medical department, Klinikum Klagenfurt, Klagenfurt, Austria.
Sperr WR; Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
Hojas S; Department of Internal Medicine, LKH Fürstenfeld, Fürstenfeld, Austria.
Rogulj IM; Department of Hematology, Clinical Hospital Merkur, Zagreb, Croatia.
Andel J; Department of Internal Medicine II, LKH Steyr, Steyr, Austria.
Greil R; 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg, Austria.; Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute, Salzburg, Austria.; Cancer Cluster Salzburg, Salzburg, Austria.
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2016 Apr 16; Vol. 9, pp. 39. Date of Electronic Publication: 2016 Apr 16.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Azacitidine/*therapeutic use
Leukemia, Myeloid/*drug therapy
Myelodysplastic Syndromes/*drug therapy
Registries/*statistics & numerical data
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/therapeutic use ; Austria ; Female ; France ; Humans ; Kaplan-Meier Estimate ; Leukemia, Myeloid/classification ; Leukemia, Myeloid/diagnosis ; Male ; Middle Aged ; Myelodysplastic Syndromes/classification ; Myelodysplastic Syndromes/diagnosis ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Prognosis ; Proportional Hazards Models ; United Kingdom ; United States ; World Health Organization
Czasopismo naukowe
Tytuł :
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Autorzy :
Burgstaller S; Innere Medizin IV, Klinikum Wels-Grieskirchen, Grieskirchnerstraße 42, 4600 Wels, Austria. />Fridrik M
Hojas S
Kühr T
Ludwig H
Mayrbäurl B
Pöhnl R
Pötscher M
Schlögl E
Zauner D
Thaler J
Gisslinger H
Pokaż więcej
Źródło :
Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2013 Apr; Vol. 125 (7-8), pp. 196-9. Date of Electronic Publication: 2013 Mar 28.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Anemia/*chemically induced
Leukopenia/*chemically induced
Primary Myelofibrosis/*complications
Primary Myelofibrosis/*drug therapy
Thalidomide/*analogs & derivatives
Thrombocytopenia/*chemically induced
Aged ; Aged, 80 and over ; Austria ; Dose-Response Relationship, Drug ; Female ; Humans ; Immunologic Factors ; Lenalidomide ; Male ; Middle Aged ; Primary Myelofibrosis/diagnosis ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thrombocytopenia/diagnosis ; Treatment Outcome
Czasopismo naukowe
    Wyświetlanie 1-6 z 6

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies